Alector, Inc.
ALEC evidence brief
What we can confirm
- BioSniper Score:
- 4.5 / 10
- Market Cap:
- $275.8M
- Lead Asset:
- al064 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for ALEC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ALEC
Alector, Inc. is a publicly traded biotechnology company focused on developing therapies for neurodegenerative diseases, with a wholly owned blood-brain barrier platform and a pipeline of programs targeting Alzheimer's, Parkinson's, and related disorders.
Key risk: Cash runway
BioSniper Score
Based on 4 of 6 signals
Market Cap
$275.8M
Cash Runway
—
Lead Asset
al064 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 9 clinical trials for Alector, Inc..
Alector, Inc. is a publicly traded biotechnology company focused on developing therapies for neurodegenerative diseases, with a wholly owned blood-brain barrier platform and a pipeline of programs targeting Alzheimer's, Parkinson's, and related disorders.
- Cash & equivalents of $59.9M as of 2026-06-30 [sec]
- Total revenue of $3.3M and net income of -$23.0M as of 2026-06-30 [sec]
- Accumulated deficit of $1,018.0 million as of 2026-08-06 [sec_mda]
- Lead anti-amyloid beta antibody AL137 advancing toward IND submission targeted for Q1 2027 [sec_mda · as of 2026-08-06]
- Virtual R&D event scheduled for October 7, 2026 to highlight ABC-enabled pipeline including AL137, AL164, and AL062 [news · published 2026-10-07]
What works
- Alector's wholly owned ABC blood-brain barrier platform enables peripheral dosing for siRNA and antibody programs, potentially offering more convenient and scalable administration compared with intrathecal delivery [sec_mda · as of 2026-08-06]
- The company has multiple wholly owned programs advancing toward IND-enabling studies, including AL137 (anti-amyloid beta antibody) and AL050 (GCase enzyme replacement therapy) [news · published 2025-11-06]
- Alector has a pipeline of siRNA programs targeting tau, alpha-synuclein, and NLRP3 for neurodegenerative disorders [news · published 2025-11-06]
What to weigh
- Alector has an accumulated deficit of $1,018.0 million as of 2026-08-06, with net losses substantially from R&D and G&A costs [sec_mda · as of 2026-08-06]
- Cash & equivalents have declined from $354.6 million in Q1 2025 to $59.9 million as of 2026-06-30, indicating significant cash burn [news · published 2025-05-08] [sec]
- Shareholders' equity is negative at -$10.0M as of 2026-06-30, reflecting accumulated losses exceeding equity [sec]
- The company expects expenses to increase substantially as it advances preclinical studies, clinical trials, and regulatory activities [sec_mda · as of 2026-08-06]
From the filings
Quoted directly from source documents.
Accumulated deficit
“2026, we had an accumulated deficit of $1,018.0 million.”
SEC MD&A · August 6, 2026
Lead anti-amyloid beta antibody AL137 IND target
“we intend to advance AL137 for submission of an Investigational New Drug (IND) application, targeted for the first quarter of 2027.”
SEC MD&A · August 6, 2026
Virtual R&D event
“Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline”
News · October 7, 2026
Cash position decline
“Extending runway into the second half of 2027, with $354.6 million in cash, cash equivalents, and investments”
News · May 8, 2025
Catalyst timeline
- 2019-09-27 · Phase 2 start for AL001 in FTD (heterozygous carriers of GRN or C9orf72 mutations) — This is a historical catalyst; no recent update on this trial's status is provided in the chunks.
- 2021-01-22 · Phase 2 start for AL002 in early Alzheimer's disease — This is a historical catalyst; no recent update on this trial's status is provided in the chunks.
- 2021-09-02 · Phase 2 start for AL001 in C9orf72-associated ALS — This is a historical catalyst; no recent update on this trial's status is provided in the chunks.
- 2023-01-04 · Phase 2 start for a multicenter, long-term study — This is a historical catalyst; no recent update on this trial's status is provided in the chunks.
Risks & what to watch (4)›
Key risks
- Cash runway — Cash & equivalents dropped from $354.6M (Q1 2025) to $59.9M (2026-06-30), raising concerns about near-term funding [news · 2025-05-08] [sec]
- Negative equity — Shareholders' equity of -$10.0M as of 2026-06-30 indicates liabilities exceed assets [sec]
- Rising expenses — Expenses expected to increase substantially as the company advances R&D and regulatory activities [sec_mda · 2026-08-06]
- Clinical trial risk — Key Phase 2/3 trials (e.g., INFRONT-3, PROGRESS-AD) have not yet reported topline data; delays or negative outcomes could impair pipeline value [news · 2025-08-07]
What to watch
- Topline data from the INFRONT-3 Phase 3 trial of latozinemab in FTD-GRN, previously on track for Q4 2025 [news · published 2025-08-07]
- Completion of the PROGRESS-AD Phase 2 trial of AL101 in early Alzheimer's disease, expected in 2026 [news · published 2025-08-07]
- IND submission for AL137 targeted for Q1 2027 and first-in-human dosing in Australia no later than April 2027 [sec_mda · as of 2026-08-06]
- Virtual R&D event on October 7, 2026, which may provide updates on ABC-enabled pipeline programs [news · published 2026-10-07]
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 11, 2026 · How we verify sources →
Run Alector, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Alector, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$23M
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
0 buys · 5 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
137
Total value held
$181.0M
| Holder | Shares | Value |
|---|---|---|
| tcg crossover management, llc | 10,000,000 | $21.5M |
| blackrock, inc. | 7,741,245 | $16.6M |
| foresite capital management iv, llc | 3,887,200 | $8.4M |
| vanguard capital management llc | 3,678,722 | $7.9M |
| merck & co., inc. | 3,545,719 | $7.6M |
| d. e. shaw & co., inc. | 3,332,835 | $7.2M |
| 683 capital management, llc | 3,200,000 | $6.9M |
| balyasny asset management l.p. | 2,935,253 | $6.3M |
| nantahala capital management, llc | 2,815,983 | $6.1M |
| vanguard portfolio management llc | 2,583,542 | $5.6M |
Showing top 10 of 137 institutional holders of Alector, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 7.0%
- Days to cover
- 8.2
- Shares short
- 6,284,391
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ALEC short interestGovernance
Frequently asked questions
What is the AI investment thesis for Alector, Inc.?
Alector, Inc. is a publicly traded biotechnology company focused on developing therapies for neurodegenerative diseases, with a wholly owned blood-brain barrier platform and a pipeline of programs targeting Alzheimer's, Parkinson's, and related disorders.
What is Alector, Inc.'s lead drug candidate?
Alector, Inc.'s most advanced tracked candidate is al064 (Preclinical) for Alzheimer's disease and other tauopathies.
Who is the CEO of Alector, Inc.?
Dr. Arnon Rosenthal Ph.D. is the chief executive officer of Alector, Inc. (ALEC).
Where is Alector, Inc. headquartered?
Alector, Inc. (ALEC) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does Alector, Inc. focus on?
Alector, Inc. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.